JP2011510632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510632A5 JP2011510632A5 JP2010544476A JP2010544476A JP2011510632A5 JP 2011510632 A5 JP2011510632 A5 JP 2011510632A5 JP 2010544476 A JP2010544476 A JP 2010544476A JP 2010544476 A JP2010544476 A JP 2010544476A JP 2011510632 A5 JP2011510632 A5 JP 2011510632A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cancer
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010062164 Seronegative arthritis Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2395808P | 2008-01-28 | 2008-01-28 | |
| US61/023,958 | 2008-01-28 | ||
| US10006308P | 2008-09-25 | 2008-09-25 | |
| US61/100,063 | 2008-09-25 | ||
| US14277809P | 2009-01-06 | 2009-01-06 | |
| US61/142,778 | 2009-01-06 | ||
| PCT/US2009/032224 WO2009097325A1 (en) | 2008-01-28 | 2009-01-28 | Stabilized angiopoietin-2 antibodies and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014009633A Division JP2014128271A (ja) | 2008-01-28 | 2014-01-22 | 安定化アンジオポエチン２抗体とその用途 |
| JP2014161003A Division JP2015038067A (ja) | 2008-01-28 | 2014-08-07 | 安定化アンジオポエチン２抗体とその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510632A JP2011510632A (ja) | 2011-04-07 |
| JP2011510632A5 true JP2011510632A5 (enExample) | 2012-03-15 |
| JP5596559B2 JP5596559B2 (ja) | 2014-09-24 |
Family
ID=40913201
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544476A Expired - Fee Related JP5596559B2 (ja) | 2008-01-28 | 2009-01-28 | 安定化アンジオポエチン２抗体とその用途 |
| JP2014009633A Pending JP2014128271A (ja) | 2008-01-28 | 2014-01-22 | 安定化アンジオポエチン２抗体とその用途 |
| JP2014161003A Pending JP2015038067A (ja) | 2008-01-28 | 2014-08-07 | 安定化アンジオポエチン２抗体とその用途 |
| JP2016220483A Expired - Fee Related JP6335249B2 (ja) | 2008-01-28 | 2016-11-11 | 安定化アンジオポエチン２抗体とその用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014009633A Pending JP2014128271A (ja) | 2008-01-28 | 2014-01-22 | 安定化アンジオポエチン２抗体とその用途 |
| JP2014161003A Pending JP2015038067A (ja) | 2008-01-28 | 2014-08-07 | 安定化アンジオポエチン２抗体とその用途 |
| JP2016220483A Expired - Fee Related JP6335249B2 (ja) | 2008-01-28 | 2016-11-11 | 安定化アンジオポエチン２抗体とその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8507656B2 (enExample) |
| EP (1) | EP2247305A4 (enExample) |
| JP (4) | JP5596559B2 (enExample) |
| AU (1) | AU2009209251B8 (enExample) |
| CA (1) | CA2712000A1 (enExample) |
| MX (1) | MX2010008099A (enExample) |
| RU (1) | RU2509085C2 (enExample) |
| WO (1) | WO2009097325A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| HRP20110859T1 (hr) * | 2004-12-21 | 2011-12-31 | Medimmune Limited | Protutijela usmjerena na angiopoietin-2 i njihova upotreba |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| GEP20156390B (en) | 2008-01-03 | 2015-11-10 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| EP2247305A4 (en) * | 2008-01-28 | 2012-11-14 | Medimmune Ltd | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF |
| TW200948803A (en) * | 2008-05-07 | 2009-12-01 | Astrazeneca Ab | Chemical compounds |
| US8052645B2 (en) | 2008-07-23 | 2011-11-08 | Avant Medical Corp. | System and method for an injection using a syringe needle |
| US8177749B2 (en) | 2008-05-20 | 2012-05-15 | Avant Medical Corp. | Cassette for a hidden injection needle |
| MX2010012691A (es) | 2008-05-20 | 2011-03-30 | Avant Medical Corp Star | Sistema auto-inyector. |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| US8980268B2 (en) | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| KR101808602B1 (ko) * | 2009-10-07 | 2017-12-13 | 마크로제닉스, 인크. | 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법 |
| KR101688522B1 (ko) * | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| CA2797247C (en) * | 2010-04-28 | 2019-10-22 | Sunnybrook Health Sciences Centre | Methods and uses of tie2 binding and/or activating agents |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| WO2012137993A1 (en) * | 2011-04-05 | 2012-10-11 | Neopharm Co., Ltd. | Antibodies against angiopoietins 1 and 2, and their use |
| CA2833748C (en) * | 2011-04-20 | 2019-07-16 | Amgen Inc. | Autoinjector apparatus |
| CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| MY164611A (en) * | 2012-01-23 | 2018-01-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| EP2822594A4 (en) * | 2012-03-08 | 2016-02-17 | Medimmune Llc | METHODS OF TREATMENT WITH ANTI-ANGIOPOIETIN-2 ANTIBODIES |
| USD898908S1 (en) | 2012-04-20 | 2020-10-13 | Amgen Inc. | Pharmaceutical product cassette for an injection device |
| USD808010S1 (en) | 2012-04-20 | 2018-01-16 | Amgen Inc. | Injection device |
| WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| SG11201408538PA (en) | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| UA128182C2 (uk) | 2012-11-13 | 2024-05-01 | Біонтех Аґ | Агенти для лікування експресуючих клаудин ракових захворювань |
| US11091809B2 (en) * | 2012-12-03 | 2021-08-17 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
| JP6326066B2 (ja) * | 2012-12-20 | 2018-05-16 | メディミューン，エルエルシー | 凝集プロファイルが改善されている液状抗体製剤 |
| JP6336564B2 (ja) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入器、および自動注入器システム |
| US10492990B2 (en) | 2013-03-15 | 2019-12-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| DK2983695T3 (da) | 2013-04-11 | 2019-09-02 | Sunnybrook Res Inst | Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister |
| KR102131371B1 (ko) * | 2013-07-02 | 2020-07-08 | 삼성전자주식회사 | Ang-2 특이적 항체 및 그의 용도 |
| US9902767B2 (en) | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| KR102206029B1 (ko) | 2014-01-27 | 2021-01-20 | 삼성전자주식회사 | Ang-2에 특이적으로 결합하는 항체 및 그의 용도 |
| CA2946906A1 (en) * | 2014-05-07 | 2015-11-12 | Medimmune, Llc | Methods of using anti-ang2 antibodies |
| AR100270A1 (es) | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| EP3207059A1 (en) | 2014-10-17 | 2017-08-23 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
| EP4606820A3 (en) | 2015-11-30 | 2025-10-29 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| CN109863171B (zh) | 2016-08-23 | 2023-08-04 | 免疫医疗有限公司 | 抗vegf-a和抗ang2抗体及其用途 |
| CA3040914A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| KR102589422B1 (ko) * | 2017-01-09 | 2023-10-13 | 바이오뮤넥스 파마슈티컬스 | 다중특이적 항체를 제조하기 위한 폴리펩티드 링커 |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| AU2018275891B2 (en) | 2017-06-02 | 2025-02-27 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| AU2018291032A1 (en) | 2017-06-29 | 2020-01-16 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| US20210071258A1 (en) | 2017-09-01 | 2021-03-11 | Juno Therapeutics, Inc. | Gene expression and assessment of risk of developing toxicity following cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| IL283298B2 (en) | 2018-11-30 | 2025-03-01 | Juno Therapeutics Inc | Methods for dosing and treating B-cell malignancies with adoptive cell therapy |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| AU2020395318A1 (en) | 2019-12-06 | 2022-06-09 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating B cell malignancies |
| CN113087696A (zh) * | 2019-12-23 | 2021-07-09 | 江苏开元药业有限公司 | 喹啉类化合物及其应用 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN116472285A (zh) * | 2020-08-07 | 2023-07-21 | 南京金斯瑞生物科技有限公司 | 针对人血管生成素-2的抗体及其用途 |
| WO2024077286A2 (en) * | 2022-10-07 | 2024-04-11 | The Regents Of The University Of California | Compositions and methods for detection and treatment of prostate cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US5650490A (en) | 1994-10-07 | 1997-07-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 2 |
| EP0821728B1 (en) | 1995-04-06 | 2004-08-11 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligands, methods of making and uses thereof |
| RU2242514C2 (ru) * | 1996-07-02 | 2004-12-20 | Ридженерон Фармасьютикалз, Инк. | Изолированный tie-лиганд-4 и его изолированный фибриногеноподобный домен; изолированная молекула нуклеиновой кислоты, кодирующая указанный лиганд; вектор, содержащий указанную нуклеиновую кислоту; способ получения клетки-хозяина, трансформированной указанным вектором; способ получения tie-лиганда-4; конъюгат, содержащий указанный лиганд; лиганд-тело, содержащее указанный фибриногеноподобный домен |
| CA2368670C (en) | 1999-03-26 | 2012-06-05 | Chitra Suri | Modulation of vascular permeability by means of tie2 receptor activators |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| ES2262518T5 (es) | 1999-06-07 | 2009-05-08 | Immunex Corporation | Antagonistas de tek. |
| US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| US6808902B1 (en) * | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| US7642278B2 (en) * | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US7485297B2 (en) | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
| HRP20110859T1 (hr) * | 2004-12-21 | 2011-12-31 | Medimmune Limited | Protutijela usmjerena na angiopoietin-2 i njihova upotreba |
| DK1933871T3 (da) * | 2005-09-07 | 2013-07-08 | Amgen Fremont Inc | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
| WO2007075323A2 (en) | 2005-12-12 | 2007-07-05 | Okalebo Lorna Ikel | Systems and methods for maintaining and accessing medical information |
| JP5179373B2 (ja) * | 2005-12-15 | 2013-04-10 | アストラゼネカ アクチボラグ | 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ |
| US7951918B2 (en) * | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| WO2007134050A2 (en) * | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP2247305A4 (en) * | 2008-01-28 | 2012-11-14 | Medimmune Ltd | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF |
| EP2248319B1 (en) | 2008-01-28 | 2013-07-24 | Research In Motion Limited | Providing session initiation protocol request contents method and system |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
-
2009
- 2009-01-28 EP EP09706411A patent/EP2247305A4/en not_active Ceased
- 2009-01-28 WO PCT/US2009/032224 patent/WO2009097325A1/en not_active Ceased
- 2009-01-28 AU AU2009209251A patent/AU2009209251B8/en not_active Ceased
- 2009-01-28 CA CA2712000A patent/CA2712000A1/en not_active Abandoned
- 2009-01-28 RU RU2010135624/10A patent/RU2509085C2/ru not_active IP Right Cessation
- 2009-01-28 MX MX2010008099A patent/MX2010008099A/es active IP Right Grant
- 2009-01-28 US US12/864,544 patent/US8507656B2/en not_active Expired - Fee Related
- 2009-01-28 JP JP2010544476A patent/JP5596559B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-01 US US13/932,485 patent/US20130280251A1/en not_active Abandoned
-
2014
- 2014-01-22 JP JP2014009633A patent/JP2014128271A/ja active Pending
- 2014-08-07 JP JP2014161003A patent/JP2015038067A/ja active Pending
-
2016
- 2016-10-27 US US15/335,610 patent/US10329345B2/en not_active Expired - Fee Related
- 2016-11-11 JP JP2016220483A patent/JP6335249B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510632A5 (enExample) | ||
| RU2010135624A (ru) | Стабилизированные антитела против ангиопоэтина-2 и их применение | |
| Iizasa et al. | Epstein-Barr Virus (EBV)-associated gastric carcinoma | |
| Zhou et al. | Changes in marine productivity and redox conditions during the Late Ordovician Hirnantian glaciation | |
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| JP2015516801A5 (enExample) | ||
| MX357010B (es) | Anticuerpos monoclonales para tratamiento de cancer. | |
| PH12016500759A1 (en) | Oncolytic adenoviruses armed with heterologous genes | |
| JP2015119705A5 (enExample) | ||
| JP2011083291A5 (enExample) | ||
| NZ586053A (en) | Anti-vegf antibody compositions and methods | |
| WO2012054084A3 (en) | Antibodies | |
| PH12013500410B1 (en) | Vegf-binding molecules | |
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| HRP20171611T1 (hr) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidi i n-(4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidi i njihova terapeutska primjena | |
| TN2011000524A1 (en) | Antibodies specific to cadherin -17 | |
| WO2015108998A3 (en) | Cartilage targeting agents and their use | |
| JP2018516994A5 (enExample) | ||
| JP2008508858A5 (enExample) | ||
| JP2017534259A5 (enExample) | ||
| EP2592138A4 (en) | Mutant microorganism having a hydrocarbon-generating ability and method for producing hydrocarbon using same | |
| JP2014532706A5 (enExample) | ||
| JP2016531563A5 (enExample) | ||
| CY1119351T1 (el) | Αντισωματα σε adp-ριβοζυλ κυκλαση 2 | |
| BR112013021860A2 (pt) | anticorpo anti-tnfalpha humanizado |